ASCO Gastrointestinal Cancers Symposium 2026: key results and trends

Median PFS was 30.0 and 4.3 months, ORR was 80.6% v 46%, and DCR at 12 months was 62.9% v 32.4% in the FFX/bev+atezo arm compared to the atezo-only arm, respectively.

Median DMFS was NR (95% CI, 58.7 to NR) with pembrolizumab vs NR (95% CI, 59.0 to NR) with placebo (HR 0.98; 95% CI, 0.77-1.24), with 48 mo DMFS rate of 71% vs 70%.

EFS was improved with D + FLOT vs P + FLOT in pts who completed all FLOT (n=228 vs 243; hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.49–0.94), stopped some FLOT (n=63 vs 60; HR, 0.35; 95% CI, 0.16–0.71) or stopped all FLOT (n=183 vs 167; HR, 0.72; 95% CI, 0.55–0.95).

The analysis showed that FRU plus paclitaxel had a numerical improvement in PFS compared to RAM plus paclitaxel (HR 0.78, 95% CI 0.58-1.04; p = 0.09), with a statistically significant RMST advantage of 1.18 months at 20 months (95% CI 0.08-2.27; p = 0.024).

Grade ≥3 treatment-related AEs (TRAEs) occurred in 71.8% of pts with zanidatamab + tislelizumab + CT, 59.0% with zanidatamab + CT, and 59.6% with tras + CT.

The 3 and 5-year disease-free survival were 71.2% (66.5-76.3) and 66.2% (61.2-71.6) in the SOX group, as compared with 65.1% (60.2-70.5) and 55.6% (50.4-61.3) in the S-1 group.

The ORR was 11.0% (6/51) vs. 0 (0/51), and DCR was 66.7% (34/51) vs. 29.4% (15/51) in the combination group and the regorafenib group, separately, in the ITT analysis.

The 1-yr OS rate was 44.1% with elraglusib/GnP vs 22.3% with GnP; the mOS was 10.1 mo with elraglusib/GnP vs 7.2 mo with GnP (HR, 0.62; p=0.01) with approximately 79% events recorded (25.8% of pts on elraglusib/GnP and 10.3% on GnP were censored with the majority at >12 mo OS).

pCR rates were 50% (9/18) versus 42% (10/24), and MPR rates were 78% (14/18) versus 63% (15/24), respectively.

There was no significant difference in ORR (5.4% vs 9.1%, P = 0.489) and DCR (50.0% vs 47.3%, P = 0.850) between both arms.

The 3-year EFS was 74.7% (95% CI: 63.6–87.7%) in the toripalimab plus chemotherapy group and 56.2% (95% CI: 43.3–73.0%) in the chemotherapy group, with a hazard ratio (HR) of 0.52 (95% CI: 0.27–1.00; P = 0.047).

The most common TEAE were white blood cell decreased (51.9% vs. 50.0%), anemia (44.4% vs. 42.9%) and neutrophil count decreased (40.7% vs. 42.9%).